InvestorsHub Logo
Followers 0
Posts 525
Boards Moderated 0
Alias Born 05/06/2013

Re: dmattingly62 post# 42096

Wednesday, 09/18/2013 5:10:36 PM

Wednesday, September 18, 2013 5:10:36 PM

Post# of 403308
Dmatt, there was once a article that wrote about market cap. of small preclinical companies that started human trials at Harvard. I cannot find the article now, but if anyone out there has it I would appreciate it if you could post it!

In that piece it was highlighted that CTIX had only ~1/3-1/2 the market cap. of other companies entering trials at Harvard. CTIX was greatly undervalued compared to its peers. Moreover the other companies drugs had nothing near the potential of Kevetrin. If I recall it correctly the others were all cancer drugs but for more rare indications. Nowhere near a drug that could potentially treat 1/2 the known cancers and be a MAJOR SCIENTIFIC BREAKTHOUGH!

IMO, in terms of pps/market cap the company gets little to no credit for the fact that the K trial is being ran at Harvard. Not much value is given to the fact that Kevetrin can potentially be a treatment for so many cancers, nothing for future potential sells even greatly discounted by the fact that is still in p1. No hype whatsoever! This is if you just factor in Kevetrin excluding the rest of the pipeline!

There is something hanging-over this company that in my many years here I cannot put my finger on. The stock hovers around $2 now because of a small float and retail longs that are true believers. I recall when I read that article I thought based on this CTIX should have at least a 1 billion dollar market cap even before the Harvard trial begins! If you don't believe this is possible you may have been invested in CTIX too long, last part is a joke, sort of?

IMO, just Ranting

ps I am out in the woods working this week if know one else posts that article I will look for it this weekend.

Volume:
Day Range:
Bid:
Ask:
Last Trade Time:
Total Trades:
  • 1D
  • 1M
  • 3M
  • 6M
  • 1Y
  • 5Y
Recent IPIX News